nach oben

Arthritis Research & Therapy

Erschienen in:

01.02.2002 | Review

Drugs in development: bisphosphonates and metalloproteinase inhibitors

verfasst von: Jon B Catterall, Tim E Cawston

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2002

Einloggen, um Zugang zu erhalten

Abstract

The destruction of bone and cartilage is characteristic of the progression of musculoskeletal diseases. The present review discusses the developments made with two different classes of drugs, the bisphosphonates and matrix metalloproteinase inhibitors. Bisphosphonates have proven to be an effective and safe treatment for the prevention of bone loss, especially in osteoporotic disease, and may have a role in the treatment of arthritic diseases. The development of matrix metalloproteinase inhibitors and their role as potential therapies are also discussed, especially in the light of the disappointing human trials data so far published.

Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K: The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000, 39: 122-132. 10.1093/rheumatology/39.2.122.PubMed

Prockop DJ: What holds us together? Why do some of us fall apart? What can we do about it?. Matrix Biol. 1998, 16: 519-528. 10.1016/S0945-053X(98)90064-6.PubMed

Hardingham TE, Fosang AJ: Proteoglycans – many forms and many functions. Faseb J. 1992, 6: 861-870.PubMed

Barrett AJ, Rawlings ND, Woessner JF: Introduction. In Handbook of Protolytic Enzymes. 1998, London: Academic Press, xxv-xxix.

Gravallese EM, Goldring SR: Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2143-2151. 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.3.CO;2-J.PubMed

Everts V, Delaisse JM, Korper W, Niehof A, Vaes G, Beertsen W: Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol. 1992, 150: 221-231. 10.1002/jcp.1041500202.PubMed

Turk V, Turk B, Turk D: Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001, 20: 4629-4633. 10.1093/emboj/20.17.4629.PubMedCentralPubMed

Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP: Human cathepsin k cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J. 1998, 331: 727-732.PubMedCentralPubMed

Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, Bromme D, Gay S: Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol. 1998, 25: 1887-1894.PubMed

10.

Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, Keysser M, Keyszer G, Bromme D: Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol. 2001, 159: 2167-2177.PubMedCentralPubMed

11.

Fleisch H: Bisphosphonates: mechanisms of action. Endocrine Rev. 1998, 19: 80-100. 10.1210/er.19.1.80.

12.

Russell RGG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999, 25: 97-106. 10.1016/S8756-3282(99)00116-7.PubMed

13.

Fleisch H, Russell RGG, Bisaz S, Casey PA, Muhlbauer RC: The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res. 1968, 2: 10A-

14.

Fleisch H, Russell RGG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969, 165: 1262-1264.PubMed

15.

Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H: The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 1970, 6: 183-196.PubMed

16.

van Beek ER, Lowik CWGM, Ebetino FH, Papapoulos SE: Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure–activity relationships. Bone. 1998, 23: 437-442. 10.1016/S8756-3282(98)00120-3.PubMed

17.

Fleisch H: Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 1997, New York: The Parthenon Publishing Group

18.

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA. 1999, 96: 133-138. 10.1073/pnas.96.1.133.PubMedCentralPubMed

19.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action – alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105.PubMedCentralPubMed

20.

Sato M, Grasser W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light-microscopy. J Bone Miner Res. 1990, 5: 31-40.PubMed

21.

Schenk R, Merz WA, Muhlbauer RC, Russell RGG, Fleisch H: Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichlorormethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 1973, 11: 196-214.PubMed

22.

Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T: A possible mechanism of the specific action of bisphosphonates on osteoclasts – tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995, 17: 137-144. 10.1016/S8756-3282(95)00150-6.PubMed

23.

Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A: Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996, 11: 535-543.PubMed

24.

Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997, 20: 399-404. 10.1016/S8756-3282(97)00025-2.PubMed

25.

Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997, 54: 721-727. 10.1016/S0006-2952(97)00225-6.PubMed

26.

Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC: Bisphosphonates directly inhibit the bone-resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990, 85: 456-461.PubMedCentralPubMed

27.

David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H⁺-ATPase. J Bone Miner Res. 1996, 11: 1498-1507.PubMed

28.

Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone inhibition by alendronate and calcitonin. J Clin Invest. 1995, 96: 2277-2283.PubMedCentralPubMed

29.

Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995, 10: 1478-1487.PubMed

30.

Coxon FP, Benford HL, Russell RGG, Rogers MJ: Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol. 1998, 54: 631-638.PubMed

31.

Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RGG: Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res. 1996, 11: 1482-1491.PubMed

32.

Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.PubMed

33.

Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ: The bisphosphonate incadronate (ym175) causes apoptosis of human myeloma cells in vitro by inhibiting the meval-onate pathway. Cancer Res. 1998, 58: 5294-5297.PubMed

34.

Hughes DE, MacDonald BR, Russell RGG, Gowen M: Inhibition of osteoclast-like cell-formation by bisphosphonates in long-term cultures of human-bone marrow. J Clin Invest. 1989, 83: 1930-1935.PubMedCentralPubMed

35.

Boonekamp PM, Van Der Weepals LJA, Van Wijkvanlennep MML, Thesing CW, Bijvoet OLM: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986, 1: 27-39.PubMed

36.

Lowik CWGM, Van Der Plumijm G, Van Der Weepals LJA, Van Treslongdegroot HB, Bijvoet OLM: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts – the effect of a bisphosphonate. J Bone Miner Res. 1988, 3: 185-192.PubMed

37.

Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM: Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res. 1989, 4: 775-781.PubMed

38.

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000, 373: 231-241. 10.1006/abbi.1999.1502.PubMed

39.

Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem. 1996, 65: 241-269. 10.1146/annurev.bi.65.070196.001325.PubMed

40.

Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth-factors. Cell. 1992, 70: 389-399. 10.1016/0092-8674(92)90163-7.PubMed

41.

Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A: The small GTP-binding protein rac regulates growth-factor induced membrane ruffling. Cell. 1992, 70: 401-410. 10.1016/0092-8674(92)90164-8.PubMed

42.

Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ: The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate – evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001, 44: 2201-2210. 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E.PubMed

43.

Rogers MJ, Russell RGG, Blackburn GM, Williamson MP, Watts DJ: Metabolism of halogenated bisphosphonates by the cellular slime-mold dictyostelium-discoideum. Biochem Biophys Res Commun. 1992, 189: 414-423. 10.1016/0006-291X(92)91574-A.PubMed

44.

Rogers MJ, Ji XH, Russell RGG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH, Watts DJ: Incorporation of bisphosphonates into adenine-nucleotides by amebas of the cellular slime-mold dictyostelium-discoideum. Biochem J. 1994, 303: 303-311.PubMedCentralPubMed

45.

Auriola S, Frith J, Rogers MJ, Koivuniemi A, Monkkonen J: Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatographyelectrospray mass spectrometry. J Chromatogr B. 1997, 704: 187-195. 10.1016/S0378-4347(97)00490-8.

46.

Frith JC, Monkkonen J, Blackburn GM, Russell RGG, Rogers MJ: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997, 12: 1358-1367.PubMed

47.

Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973, 11: 269-280.PubMed

48.

Van Beek E, Hoekstra M, Van De Ruit M, Lowik C, Papapoulos S: Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 1994, 9: 1875-1882.PubMed

49.

Garnero P, Shih WCJ, Gineyts E, Karpf DB, Delmas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994, 79: 1693-1700. 10.1210/jc.79.6.1693.PubMed

50.

Reitsma PH, Bijovoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA: Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (apd) in rats. Calcif Tissue Int. 1980, 32: 145-157.PubMed

51.

Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA: The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman-primates. J Clin Invest. 1993, 92: 2577-2586.PubMedCentralPubMed

52.

Brommage R, Baxter DC: Inhibition of bone mineral loss during lactation by cl2mbp. Calcif Tissue Int. 1990, 47: 169-172.PubMed

53.

Jee WSS, Black HE, Gotcher JE: Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young-adult rabbits. Clin Orthopaed Relat Res. 1981, 156: 39-51.

54.

Muhlbauer RC, Russell RGG, Williams DA, Fleisch H: The effects of diphosphonates, polyphosphates and calcitonin on 'immobilisation osteoporosis' in rats. Eur J Clin Invest. 1971, 1: 336-344.PubMed

55.

Wink CS, Stonge M, Parker B: The effects of dichloromethylene biphosphonate on osteoporotic femora of adult castrate male-rats. Acta Anatomica. 1985, 124: 117-121.PubMed

56.

Wronski TJ, Dann LM, Scott KS, Crooke LR: Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats. Endocrinology. 1989, 125: 810-816.PubMed

57.

Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, Boldrini S, Troiani S, Massoni C: Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone. 1996, 18: 179-184. 10.1016/8756-3282(95)00442-4.PubMed

58.

Harris ST, Watts NB, Jackson RD, Genant HK, Wasnick RD, Ross P, Miller PD, Licatta AA, Chestnut CH: 4-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis – 3 years of blinded therapy followed by one-year of open therapy. Am J Med. 1993, 95: 557-567. 10.1016/0002-9343(93)90350-X.PubMed

59.

Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguezportales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB: Effect of oral alendronate on bone-mineral density and the incidence of fractures in post-menopausal osteoporosis. N Engl J Med. 1995, 333: 1437-1443. 10.1056/NEJM199511303332201.PubMed

60.

Ravn P, Clemmesen B, Riis BJ, Christiansen C: The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996, 19: 527-533. 10.1016/S8756-3282(96)00229-3.PubMed

61.

Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J: Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994, 79: 1595-1599. 10.1210/jc.79.6.1595.PubMed

62.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH: Intermittent cyclical etidronate treatment of post-menopausal osteoporosis. N Engl J Med. 1990, 323: 73-79.PubMed

63.

Reid IR, Alexander CJ, King AR, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (apd). Lancet. 1988, 1: 143-146. 10.1016/S0140-6736(88)92721-3.PubMed

64.

Ammann P, Rizzoli R, Caverzasio J, Shigematsu T, Slosman D, Bonjour JP: Effects of the bisphosphonate tiludronate on bone-resorption, calcium balance, and bone-mineral density. J Bone Miner Res. 1993, 8: 1491-1498.PubMed

65.

Ferretti JL, Delgado CJ, Capozza RF, Cointry G, Montuori E, Roldan E, Lloret AP, Zanchetta JR: Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner. 1993, 20: 265-276.PubMed

66.

Motoie H, Nakamura T, Ouchi N, Nishikawa H, Kanoh H, Abe T, Kawahima H: Effects of the bisphosphonate ym175 on bone-mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res. 1995, 10: 910-920.PubMed

67.

Toolan BC, Shea M, Myers ER, Borchers RE, Seedor JG, Quartuccio H, Rodan G, Hayes WC: Effects of 4-amino-1-hydroxy-butylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res. 1992, 7: 1399-1406.PubMed

68.

Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996, 334: 488-493. 10.1056/NEJM199602223340802.PubMed

69.

Dunn CJ, Fitton A, Sorkin EM: Etidronic acid – a review of its pharmacological properties and therapeutic efficacy in resorptive bone-disease. Drugs Aging. 1994, 5: 446-474.PubMed

70.

Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.PubMed

71.

Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, TubianaHulin M, Steinhauer EU, vanEijkeren M, Huss HJ, Thiebaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 1996, 14: 268-276.PubMed

72.

Plosker GL, Goa KL: Clodronate – a review of its pharmacological properties and therapeutic efficacy in resorptive bone-disease. Drugs. 1994, 47: 945-982.PubMed

73.

Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP: Role of cd47 as a marker of self on red blood cells. Science. 2000, 288: 2051-2056. 10.1126/science.288.5473.2051.PubMed

74.

Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Love WG, Williams BD: The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clin Exp Immunol. 1995, 99: 269-275.PubMedCentralPubMed

75.

Kinne RW, SchmidtWeber CB, Hoppe R, Buchner E, PalomboKinne E, Nurnberg E, Emmrich F: Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum. 1995, 38: 1777-1790.PubMed

76.

Van Lent PLEM, Vandenbersselaar L, Van Denhoek AEM, Van Deende M, Dijkstra CD, Van Rooijen N, Van Deputte LBA, Van Den Berg WB: Reversible depletion of synovial lining cells after intraarticular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheum Int. 1993, 13: 21-30. 10.1007/BF00290330.

77.

Barrera P, Blom A, van Lent PLEM, van Bloois L, Beijnen JH, van Rooijen N, Malefijt MCD, van de Putte LBA, Storm G, van den Berg WB: Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 1951-1959. 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K.PubMed

78.

Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 115-124.PubMed

79.

Yanni G, Whelan A, Feighery C, Bresnihan B: Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis. 1994, 53: 39-44.PubMedCentralPubMed

80.

Fleisch H, Russell RGG, Bisaz S, Muhlbauer RC, Williams DA: The inhibitory effect of bisphosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1970, 1: 12-18.PubMed

81.

Rosenblum IY, Black HE, Ferrell JF: The effects of various diphosphates on rat model of cardiac calciphylaxis. Calcif Tissue Res. 1977, 23: 151-159.PubMed

82.

Levy RJ, Schoen FJ, Lund SA, Smith MS: Prevention of leaflet calcification of bioprosthetic heart-valves with diphosphonate injection therapy – experimental studies of optimal dosages and therapeutic durations. J Thoracic Cardiovasc Surg. 1987, 94: 551-557.

83.

Fleisch H: Bisphosphonates: a new class of drug in diseases of bone and calcium metabolism. In Handbook of Experimental Pharmacology. 1988, New York: Springer-Verlag, 83: 440-466.

84.

Thomas BJ, Amstutz HC: Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip-arthroplasty. J Bone Joint Surg Am. 1985, 67A: 400-403.

85.

Muhlemann HR, Bowles D, Schatt A, Bernimoulin JP: Effect of diphosphonate on human supragingival calculus. Helv Odont Acta. 1970, 14: 31-33.

86.

Sturzenberger OP, Swancar JR, Reiter G: Reduction of dental calculus in humans through the use of a dentifrice containing a crystal-growth inhibitor. J Periodontol. 1971, 42: 416-419.PubMed

87.

de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, PryorTillotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med. 1996, 335: 1016-1021. 10.1056/NEJM199610033351403.PubMed

88.

Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, Ofallon WM, Riggs BL: Pamidronate – an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994, 4: 320-322. 10.1007/BF01622190.

89.

Van Breukelen FJM, Bijvoet OLM, Frijlink WB, Sleeboom HP, Mulder H, Van Oosterom AT: Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia – observations on regulation of serum-calcium. Calcif Tissue Int. 1982, 34: 321-327.PubMed

90.

Ciosek CP, Magnin DR, Harrity TW, Logan JVH, Dickson JK, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, Mookhtiar KA, Rich LC, Slusarchyk DA, Sulsky RB, Biller SA: Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally-active cholesterol-lowering agents in vivo. J Biol Chem. 1993, 268: 24832-24837.PubMed

91.

Kang TB, Nagase H, Pei DQ: Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-golgi network. Cancer Res. 2002, 62: 675-681.PubMed

92.

Santavicca M, Noel A, Angliker H, Stoll I, Segain JP, Anglard P, Chretien M, Seidah N, Basset P: Characterization of structural determinants and molecular mechanisms involved in prostromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J. 1996, 315: 953-958.PubMedCentralPubMed

93.

Wolfsberg TG, Primakoff P, Myles DG, White JM: ADAM, a novel family of membrane-proteins containing a disintegrin and metalloprotease domain – multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol. 1995, 131: 275-278. 10.1083/jcb.131.2.275.PubMed

94.

Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJP, Murphy G: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998, 435: 39-44. 10.1016/S0014-5793(98)01031-X.PubMed

95.

Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC: Purification and cloning of aggrecanase-1: a member of the ADAMts family of proteins. Science. 1999, 284: 1664-1666. 10.1126/science.284.5420.1664.PubMed

96.

Bigg HF, Rowan AD: The inhibition of metalloproteinases as a target in rheumatoid arthritis and osteoarthritis. Curr Opin Pharmacol. 2001, 1: 314-320. 10.1016/S1471-4892(01)00055-8.PubMed

97.

Fernandes JC, Martel-Pelletier J, Lascau-Coman V, Moldovan F, Jovanovic D, Raynauld JP, Pelletier JP: Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study. J Rheumatol. 1998, 25: 1585-1594.PubMed

98.

Tetlow LC, Woolley DE: Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro. Br J Rheum. 1998, 37: 64-70. 10.1093/rheumatology/37.1.64.

99.

Lindy O, Konttinen YT, Sorsa T, Ding YL, Santavirta S, Ceponis A, LopezOtin C: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 1997, 40: 1391-1399.PubMed

100.

Mitchell PG, Magna HA, Reeves LM, LoprestiMorrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996, 97: 761-768.PubMedCentralPubMed

101.

Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, Kinne RW, Santavirta S, Sorsa T, Lopez-Otin C, Takagi M: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999, 58: 691-697.PubMedCentralPubMed

102.

Konttinen YT, Ceponis A, Takagi M, Ainola M, Sorsa T, Sutinen ME, Salo T, Ma J, Santavirta S, Seiki M: New collagenolytic enzymes cascade identified at the pannus–hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol. 1998, 17: 585-601. 10.1016/S0945-053X(98)90110-X.PubMed

103.

Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, Gay S: Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 1226-1232. 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4.PubMed

104.

Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, VanWart H, Poole AR: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997, 99: 1534-1545.PubMedCentralPubMed

105.

Balbin M, Fueyo A, Knauper V, Lopez JM, Alvarez J, Sanchez LM, Quesada V, Bordallo J, Murphy G, Lopez-Otin C: Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem. 2001, 276: 10253-10262. 10.1074/jbc.M009586200.PubMed

106.

Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999, 99: 81-92. 10.1016/S0092-8674(00)80064-1.PubMed

107.

Neuhold LA, Killar L, Zhao WG, Sung MLA, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ: Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest. 2001, 107: 35-44.PubMedCentralPubMed

108.

Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998, 93: 411-422. 10.1016/S0092-8674(00)81169-1.PubMedCentralPubMed

109.

Bottomley KM, Johnson WH, Walter DS: Matrix metalloproteinase inhibitors in arthritis. J Enzyme Inhib. 1998, 13: 79-101.PubMed

110.

Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Discov Today. 1996, 1: 16-26. 10.1016/1359-6446(96)89115-X.

111.

Beckett RP, Whittaker M: Matrix metalloproteinase inhibitors 1998. Expert Opin Ther Patents. 1998, 8: 259-282.

112.

Brown PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs. 2000, 9: 2167-2177.PubMed

113.

Docherty AJP, Baker TS, Beeley NRA, Birch ML, Boyce BA, Cockett MI, Crabbe T, Eaton D, Hart IR, Hynds P, Leonard J, Mahadevan V, Mason B, Millican TA, Morphy JR, Mountain A, Murphy G, O'Connell J, Porter J, Tickle S, Ward RV, Willenbrock F, Willmott N: Gelatinase-A and the metastatic phenotype – prospects for treating invasive cancers with selective gelatinase inhibitors. Cell Biol Int. 1995, 19: 245-246.

114.

Leff RL: Clinical trials of a stromelysin inhibitor. Science. 1999, 878: 201-207.

115.

Clark IM, Rowan AD, Cawston TE: Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr Opin Anti-Inflamm Immunomod Invest Drugs. 2000, 2: 16-25.

116.

Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G: Cellular mechanisms for human procollagenase-3 (MMP-13) activation – evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem. 1996, 271: 17124-17131. 10.1074/jbc.271.29.17124.PubMed

117.

Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KMK: Ro 32–3555, an orally active collagenase selective inhibitor, prevents structural damage in the str/ort mouse model of osteoarthritis. Arthritis Rheum. 1998, 41: 1639-1644. 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0.PubMed

118.

Martel-Pelletier J, Pelletier JP: Wanted – the collagenase responsible for the destruction of the collagen network in human cartilage!. Br J Rheum. 1996, 35: 818-820.

119.

Close DR: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis. 2001, 60: iii62-iii67.PubMedCentralPubMed

120.

Greenwald RA: Treatment of destructive arthritic disorders with MMP inhibitors – potential role of tetracyclines. Inhibition of matrix metalloproteinases: therapeutic potential. Ann NY Acad Sci. 1994, 732: 181-198.PubMed

121.

Ashley RA: Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Inhibition of matrix metalloproteinases: therapeutic applications. Ann NY Acad Sci. 1999, 878: 335-346.PubMed

122.

Nakaya H, Osawa G, Iwasaki N, Cochran DL, Kamoi K, Oates TW: Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol. 2000, 71: 1158-1166. 10.1902/jop.2000.71.7.1158.PubMed

123.

Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Sorsa T: Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res. 1997, 76: 1529-1537.PubMed

124.

Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998, 4: 1101-1109.PubMed

125.

Bayer drug casts shadow over MMP inhibitors in cancer. Scrip. 1999, 2476: 7-

126.

Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljestrom M, Hukkanen M, Takagi M, Virtanen I, Santavirta S: Acidic cysteine endoproteinase cathepsin k in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002, 46: 953-960. 10.1002/art.10185.PubMed

127.

Hou WS, Li WJ, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Bromme D: Comparison of cathepsins k and s expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002, 46: 663-674. 10.1002/art.10114.PubMed

128.

Takizawa M, Ohuchi E, Yamanaka H, Nakamura H, Ikeda E, Ghosh P, Okada Y: Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2000, 43: 812-820. 10.1002/1529-0131(200004)43:4<812::AID-ANR11>3.0.CO;2-Y.PubMed

129.

Murphy G, Knauper V: Relating matrix metalloproteinase structure to function: why the 'hemopexin' domain?. Matrix Biol. 1997, 15: 511-518. 10.1016/S0945-053X(97)90025-1.PubMed

130.

Mengshol JA, Mix KS, Brinckerhoff CE: Matrix metalloproteinases as therapeutic targets in arthritic diseases – bull's-eye or missing the mark?. Arthritis Rheum. 2002, 46: 13-20. 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S.PubMed

131.

Nagase H, Meng Q, Malinovskii V, Huang W, Chung L, Bode W, Maskos K, Brew K: Engineering of selective TIMPs. Inhibition of matrix metalloproteinases: therapeutic applications. Ann NY Acad Sci. 1999, 878: 1-11.PubMed

132.

Meng Q, Malinovskii V, Huang W, Hu YJ, Chung L, Nagase H, Bode W, Maskos K, Brew K: Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding p1' residue of substrate. J Biol Chem. 1999, 274: 10184-10189. 10.1074/jbc.274.15.10184.PubMed

133.

Nagase H, Brew K: Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. The Scientific Basis of Rheumatology. Arthritis Res. 2002, 4 (suppl 3): S51-S62. 10.1186/ar573.PubMedCentralPubMed

Titel: Drugs in development: bisphosphonates and metalloproteinase inhibitors
verfasst von: Jon B Catterall
Tim E Cawston
Publikationsdatum: 01.02.2002
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 1/2002
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar604

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2002

Elucidation of the potential roles of matrix metalloproteinases in skeletal biology

The relationship between predicted peptide–MHC class II affinity and T-cell activation in a HLA-DRβ1*0401 transgenic mouse model

The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis

Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients